Alivus Life Sciences Announces Board Meeting for Q1 Results and Declares Trading Window Closure
Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has scheduled a board meeting to consider and approve its Unaudited Financial Results for the quarter ended June 30, 2026.The Board of Directors meeting is set to be held on Thursday, July 30, 2026. The purpose of the meeting is to review and approve the financial outcomes achieved during the specified quarter.
In preparation for the announcement of these results, the company has also designated a period during which trading will be restricted. Alivus Life Sciences announced the closure of its Trading Window, effective from July 1, 2026, through August 1, 2026. This restriction is in place to ensure compliance concerning the approval process for the Unaudited Financial Results for the quarter ended June 30, 2026.
ALIVUS Stock Price Movement
As of 2:39 PM, shares of Alivus Life Sciences Limited are slipping by 2.08% in live trading, currently valued at ₹1114.7, as the stock battles downward pressure this afternoon. The equity has seen a traded volume of 27,556 shares so far into the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.